BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 28279064)

  • 1. Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.
    Koo KC; Cho JS; Bang WJ; Lee SH; Cho SY; Kim SI; Kim SJ; Rha KH; Hong SJ; Chung BH
    Cancer Res Treat; 2018 Jan; 50(1):129-137. PubMed ID: 28279064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer.
    Lee JY; Cho KS; Kwon JK; Jeh SU; Kang HW; Diaz RR; Ham WS; Koom WS; Keum KC; Choi YD
    Ann Surg Oncol; 2014 Nov; 21(12):4026-33. PubMed ID: 24841351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
    Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
    Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.
    Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
    Ann Surg Oncol; 2014 Feb; 21(2):677-83. PubMed ID: 24145996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
    Moltzahn F; Karnes J; Gontero P; Kneitz B; Tombal B; Bader P; Briganti A; Montorsi F; Van Poppel H; Joniau S; Spahn M
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):31-7. PubMed ID: 25535100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.
    Bandini M; Marchioni M; Preisser F; Zaffuto E; Tian Z; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    World J Urol; 2018 Sep; 36(9):1399-1407. PubMed ID: 29717358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.
    Sheng W; Zhang H; Lu Y
    Int Urol Nephrol; 2018 Aug; 50(8):1435-1444. PubMed ID: 29982959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.
    Sheng W; Kirschner-Hermanns R; Zhang H
    World J Urol; 2019 Feb; 37(2):317-325. PubMed ID: 29951790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
    Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Hoeh B; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
    Prostate; 2022 May; 82(6):740-750. PubMed ID: 35226380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
    Wenzel M; Würnschimmel C; Chierigo F; Tian Z; Shariat SF; Terrone C; Saad F; Tilki D; Graefen M; Mandel P; Kluth LA; Chun FKH; Karakiewicz PI
    Prostate; 2021 Aug; 81(11):728-735. PubMed ID: 34010465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.
    Boehm K; Dell'Oglio P; Tian Z; Capitanio U; Chun FKH; Tilki D; Haferkamp A; Saad F; Montorsi F; Graefen M; Karakiewicz PI
    World J Urol; 2017 Jul; 35(7):1031-1036. PubMed ID: 27796538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
    Gandaglia G; Sun M; Trinh QD; Becker A; Schiffmann J; Hu JC; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI; Abdollah F
    BJU Int; 2014 Dec; 114(6b):E62-E69. PubMed ID: 24467651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation therapy after radical prostatectomy is associated with higher other-cause mortality.
    Würnschimmel C; Wenzel M; Chierigo F; Flammia RS; Horlemann B; Tian Z; Saad F; Briganti A; Shariat SF; Gallucci M; Suardi N; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
    Cancer Causes Control; 2022 May; 33(5):769-777. PubMed ID: 35230576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is radiotherapy after radical prostatectomy associated with higher other-cause mortality?
    Özman O; Droghetti M; Pos F; van Leeuwen PJ; van der Poel H
    Cancer Causes Control; 2023 Dec; 34(12):1139-1144. PubMed ID: 37522983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
    Abdollah F; Sun M; Schmitges J; Tian Z; Jeldres C; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Eur Urol; 2011 Nov; 60(5):920-30. PubMed ID: 21741762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
    Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of age and comorbidity on survival vary according to risk grouping among patients with prostate cancer treated using radical prostatectomy: A retrospective competing-risk analysis from the K-CaP registry.
    Hah YS; Lee KS; Choi IY; Lee JY; Hong JH; Kim CS; Lee HM; Hong SK; Byun SS; Lee SH; Rha KH; Chung BH; Koo KC
    Medicine (Baltimore); 2018 Oct; 97(42):e12766. PubMed ID: 30334964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.